{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Agent&page=4",
    "query": {
      "intervention": "Study Agent",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 17514,
    "total_pages": 1752,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Agent&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Agent&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T00:56:05.431Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00935766",
      "title": "Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metabolic Diseases",
        "Endocrine System Diseases",
        "Heart Disease",
        "Vascular Diseases",
        "Diabetes",
        "Cardiovascular Disease",
        "Glucose Metabolism Disorders",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Omega-3",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denver Health and Hospital Authority",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2009-09",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2014-09-29",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00935766"
    },
    {
      "nct_id": "NCT01064466",
      "title": "Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ETOPOSIDE - Usual",
          "type": "DRUG"
        },
        {
          "name": "ETOPOSIDE - Study",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "24 Years to 64 Years"
      },
      "enrollment_count": 600,
      "start_date": "2025-07-16",
      "completion_date": "2026-12-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01064466"
    },
    {
      "nct_id": "NCT04476953",
      "title": "COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fisetin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2020-08-03",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04476953"
    },
    {
      "nct_id": "NCT07513337",
      "title": "Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cannabis Use"
      ],
      "interventions": [
        {
          "name": "Strain label",
          "type": "OTHER"
        },
        {
          "name": "Claim",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins Bloomberg School of Public Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 3035,
      "start_date": "2026-04-15",
      "completion_date": "2026-07-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07513337"
    },
    {
      "nct_id": "NCT03006237",
      "title": "IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hysterectomy",
        "Surgery"
      ],
      "interventions": [
        {
          "name": "IS-001",
          "type": "DRUG"
        },
        {
          "name": "da Vinci® Si/Xi Surgical System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Intuitive Surgical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2016-12",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-03-05",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03006237"
    },
    {
      "nct_id": "NCT05274672",
      "title": "Role of Prophylactic Postoperative Antibiotics in HoLEP",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Benign Prostatic Hyperplasia",
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Nitrofurantoin",
          "type": "DRUG"
        },
        {
          "name": "Cephalexin",
          "type": "DRUG"
        },
        {
          "name": "Sulfamethoxazole Trimethoprim Combination",
          "type": "DRUG"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Holmium Laser Enucleation of prostate",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2023-03-01",
      "completion_date": "2025-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Temple, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05274672"
    },
    {
      "nct_id": "NCT00789672",
      "title": "Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amblyopia"
      ],
      "interventions": [
        {
          "name": "levodopa/carbidopa",
          "type": "DRUG"
        },
        {
          "name": "patching",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 33,
      "start_date": "2009-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00789672"
    },
    {
      "nct_id": "NCT02553265",
      "title": "Carbidopa for the Treatment of Excessive Blood Pressure Variability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dysautonomia, Familial",
        "Baroreflex Failure Syndrome"
      ],
      "interventions": [
        {
          "name": "Carbidopa Low-Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Carbidopa High-Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "10 Years to 60 Years"
      },
      "enrollment_count": 22,
      "start_date": "2015-09",
      "completion_date": "2019-05-10",
      "has_results": true,
      "last_update_posted_date": "2022-02-09",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02553265"
    },
    {
      "nct_id": "NCT01323673",
      "title": "Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dermatitis, Chronic"
      ],
      "interventions": [
        {
          "name": "clobetasol propionate 0.05%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle / Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2010-11-15",
      "completion_date": "2011-03-29",
      "has_results": true,
      "last_update_posted_date": "2018-06-20",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 10,
      "location_summary": "San Diego, California • Boynton Beach, Florida • West Palm Beach, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323673"
    },
    {
      "nct_id": "NCT05521022",
      "title": "Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyloidosis; Systemic"
      ],
      "interventions": [
        {
          "name": "AT-02",
          "type": "DRUG"
        },
        {
          "name": "AT-02 (Placebo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Attralus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2022-09-01",
      "completion_date": "2025-03-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-10-26T00:56:05.431Z",
      "location_count": 6,
      "location_summary": "Overland Park, Kansas • Baltimore, Maryland • Kansas City, Missouri + 3 more",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05521022"
    }
  ]
}